Showing results (1-10 of 311) with videos related to

Sort By:
Pageof 32
The Journal of Experimental Medicine|September 1, 1996
The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligandJ O'Connell, G C O'Sullivan, J K Collins, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 15, 1996
Regional immunosuppression in esophageal squamous cancer: evidence from functional studies with matched lymph nodesG C O'Sullivan, A R Corbett, F Shanahan, et al.
British Journal of Cancer|October 2, 2003
Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expressionA Houston, M W Bennett, G C O'Sullivan, et al.
QJM : Monthly Journal of the Association of Physicians|September 14, 2000
Bone-marrow micrometastases in patients with brain metastases from epithelial cell tumoursD Maguire, G C O'Sullivan, B McNamara, et al.
The American Journal of Gastroenterology|August 5, 2000
Bone marrow micrometastases and gastrointestinal cancer detection and significanceD Maguire, G C O'Sullivan, J K Collins, et al.
Nature Medicine|March 7, 2001
Immune privilege or inflammation? Insights into the Fas ligand enigmaJ O'Connell, A Houston, M W Bennett, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|August 31, 1999
Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattackJ O'Connell, M W Bennett, G C O'Sullivan, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|December 4, 2003
Oral immune tolerance to tumor specific antigens may confer growth advantage to esophageal and gastric cancersM G O'Brien, C G Collins, J K Collins, et al.
The British Journal of Surgery|December 21, 2000
Biological behaviour and clinical implications of micrometastasesM R Kell, D C Winter, G C O'Sullivan, et al.
Pageof 32